As the first stand-alone renal outcomes trial for a GLP-1 receptor agonist with hard renal endpoints, FLOW establishes robust evidence that semaglutide slows kidney disease progression in patients with T2DM and CKD, beyond its glucose-lowering effect. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.